Primary Androgen-Deprivation Therapy Has No Survival Benefit in Cancers Confined to Prostate

Primary androgen-deprivation therapy (PADT) for men with clinically localized prostate cancer has been to found to be of no effect while it may be of small clinical benefit to men with higher-risk disease. The risks of using PADT outweighs benefits, the researchers observed. a href="http:http://ift.tt/QBo0to" target="_blank" class="vcontentshlink"Primary ADT/a is the ...

Read More